De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

DIVA Laboratories Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Zhiheng Zhao

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	geen gegevens

Recente managementupdates

Recent updates

Should You Be Impressed By DIVA Laboratories' (GTSM:4153) Returns on Capital?

Feb 28

DIVA Laboratories, Ltd. (GTSM:4153) Stock's On A Decline: Are Poor Fundamentals The Cause?

Dec 27

Is DIVA Laboratories (GTSM:4153) Likely To Turn Things Around?

Nov 30

CEO

Zhiheng Zhao

no data

Tenure

Zhiheng Zhao is Manager of DIVA Laboratories, Ltd.

DIVA Laboratories Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

DIVA Laboratories, Ltd. Announces Change of Audit Committee and Remuneration Committee

DIVA Laboratories, Ltd. Announces Election of Directors

DIVA Laboratories, Ltd., Annual General Meeting, May 31, 2024

Less than half of directors are independent

Less than half of directors are independent

DIVA Laboratories, Ltd., Annual General Meeting, Jun 13, 2022

Recent updates

Second quarter 2024 earnings released: EPS: NT$0.52 (vs NT$0.20 in 2Q 2023)

DIVA Laboratories, Ltd. to Report Q2, 2024 Results on Aug 01, 2024

Upcoming dividend of NT$1.25 per share

DIVA Laboratories, Ltd. Announces Change of Audit Committee and Remuneration Committee

DIVA Laboratories, Ltd. Announces Election of Directors

First quarter 2024 earnings released: EPS: NT$0.42 (vs NT$0.36 in 1Q 2023)

DIVA Laboratories, Ltd. to Report Q1, 2024 Results on Apr 30, 2024

DIVA Laboratories, Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: EPS: NT$1.25 (vs NT$0.85 in FY 2022)

DIVA Laboratories, Ltd., Annual General Meeting, May 31, 2024

Third quarter 2023 earnings released: EPS: NT$0.33 (vs NT$0.39 in 3Q 2022)

Second quarter 2023 earnings released: EPS: NT$0.20 (vs NT$0.059 in 2Q 2022)

Investor sentiment improves as stock rises 16%

Upcoming dividend of NT$1.00 per share at 2.6% yield

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improves as stock rises 21%

Full year 2022 earnings released: EPS: NT$0.85 (vs NT$0.37 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: NT$0.39 (vs NT$0.27 in 3Q 2021)

Second quarter 2022 earnings released: EPS: NT$0.06 (vs NT$0.11 in 2Q 2021)

Upcoming dividend of NT$0.37 per share

First quarter 2022 earnings released: EPS: NT$0.03 (vs NT$0.002 in 1Q 2021)

Less than half of directors are independent

DIVA Laboratories, Ltd., Annual General Meeting, Jun 13, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: EPS NT$0.27 (vs NT$0.02 in 3Q 2020)

Upcoming dividend of NT$0.26 per share

Second quarter 2021 earnings released: EPS NT$0.11 (vs NT$0.35 in 2Q 2020)

Full year 2020 earnings released: EPS NT$0.26 (vs NT$0.93 in FY 2019)

Should You Be Impressed By DIVA Laboratories' (GTSM:4153) Returns on Capital?

New 90-day low: NT$22.85

New 90-day low: NT$23.25

DIVA Laboratories, Ltd. (GTSM:4153) Stock's On A Decline: Are Poor Fundamentals The Cause?

New 90-day low: NT$23.90

New 90-day low: NT$26.60

Is DIVA Laboratories (GTSM:4153) Likely To Turn Things Around?

Third quarter 2020 earnings released: EPS NT$0.02

Upcoming Dividend of NT$1.66 Per Share

New 90-day low - NT$21.40

First half earnings released

CEO

Tenure